- CrucialTrak BACS Access System provides a safer and more advanced security system to the Polus biosimilar manufacturing complex.
- The completion of the new biosimilar manufacturing factory by Polus and strengthening of the 'Biometric Authentication Security Automation System'
CrucialTrak announced that the biopharmaceutical company Polus adopted the new models of CrucialTrak: Solo Palm, SpeedTrak: RoboArm and Slim Sliding, at their new factory in Hwaseong-si for the manufacture of microorganism based biosimilars at the second high-tech industrial complex. Solo Palm supports palm vein biometric authentication and the conventional RFID which will be used by more than 1,000 people including staff and visitors. Also through CruAmrs, a cloud base automated service, they will provide multi-level of physical and information security.
The current card and card reader system that the majority of domestic pharmaceutical companies used were considered as inconvenient as users required to carry a card or memorize changing password, and for the company, it was burdened of expenditures for security code tracking. The Solo Palm, touchless high-speed palm vein biometric authentication security system will provide companies the ability to continue to use the system without worrying misusage of security token by employees or false authentication and further management with one simple enrollment at the beginning of initiating the system. Also, non-contact authentication is not affected by dirt, greases, contagious infection, and other factors that reduce the accuracy of recognition systems and provide perfect hygiene for users.
The integration of the biometric system and RFID card reduces detriment of the customer experience of card to biometric transition and allows the differentiation level of security to necessary access points for example, main entrance where many daily passengers go through, and lab where only few authorized people should be accessed.
CrucialTrak Korea will be introducing the biometric security technology and the new product line up to domestic and global partner and suppliers through the 2018 Global Channel Conference on coming 1st of November.
* Polus Inc. operates as a biopharmaceutical company. The company provides therapeutic protein-based biosimilar products using large scales cell-culture technology to carry out global commercialization. It offers PDP808 which is insulin-glargine biosimilar. Polus Inc. was founded in 2016 and is based in Incheon, South Korea. (from Bloomberg)